Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: A single-center pilot study

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 341-349

  Wieland, Eberhard ^a   Shipkova, Maria ^a   Martius, Yanina ^a   Hasche, Georg ^b   Klett, Corinne ^a   Bolley, Renate ^a   Olbricht, Christoph J ^a  

^a KLINIKUM STUTTGART   (Germany)

^b Nephrologisches Zentrum Wolframstraße   (Germany)

Author keywords

Biomarkers; Cell activation; Immunosuppression; Individualization; Pharmacodynamics; Therapeutic drug monitoring

Indexed keywords

BASILIXIMAB; CD71 ANTIGEN; CELL SURFACE MARKER; DIPEPTIDYL PEPTIDASE IV; INOSINATE DEHYDROGENASE; INTERLEUKIN 2 RECEPTOR ALPHA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYFORIC; PHYTOHEMAGGLUTININ; PREDNISOLONE SODIUM SUCCINATE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION COMPLICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MONONUCLEAR CELL; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIGENS, CD; ANTIGENS, CD3; BIOLOGICAL MARKERS; CELL PROLIFERATION; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 80051801794     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182188675     Document Type: Article

References (44)

1. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit. 2006;28:720-725. (Pubitemid 44967650)
2. Pai SY, Fruman DA, Leong T, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994;84:3974-3979. (Pubitemid 24362500)
3. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
4. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999;45:1477-1484. (Pubitemid 29419000)
5. Härtel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem. 2002;48:2225-2231. (Pubitemid 35397566)
6. Yatscoff RW, Gallant HL. P70 S6 kinase assay: a pharmacodynamic monitoring strategy for rapamycin; assay development. Transplant Proc. 1996;28:3058-3061. (Pubitemid 26415395)
7. Eugui EM, Mirkovich A, Allison A. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol. 1991;33:175-183.
8. Eugui EM, Almquist S, Mullen G, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991;33: 161-173.
9. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5'-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549. (Pubitemid 34014847)
10. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant. 2004;4:2045-2051. (Pubitemid 39611633)
11. Stalder M, Birsan T, Holm B, et al. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit. 2003;25:22-27. (Pubitemid 36139821)
12. Barten MJ, Shipkova M, Bartsch P, et al. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. Ther Drug Monit. 2005;27:123-131.
13. Barten MJ, Tarnok A, Garbade J. et al. Pharmacodynamics of T-cell function for monitoring immunosuppression. Cell Prolif. 2007;40:50-63. (Pubitemid 46103690)
14. Barten MJ, Rahmel A, Bocsi J, et al. Cytokine analysis to predict immunosuppression. Cytometry A. 2006;69:155-157.
15. Barten MJ, Gummert JF. Biomarkers in transplantation medicine: prediction of pharmacodynamic drug effects. Transfus Med Hemother. 2007;34:182-187. (Pubitemid 46883383)
16. Böhler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit. 2007;29:77-86. (Pubitemid 46279880)
17. Böhler T, Canivet C, Galvani S, et al. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients. Int Immunopharmacol. 2008; 8:769-773.
18. Ohnuma K, Takahashi N, Yamochi T, et al. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci. 2008; 13:2299-2310. (Pubitemid 351589255)
19. Oellerich M, Barten MJ, Armstrong VW. Biomarkers: the link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit. 2006;28:35-38. (Pubitemid 44391691)
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
21. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998;44:1481-1488. (Pubitemid 28309109)
22. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77-89.
23. Heinschink A, Raab M, Daxecker H, et al. In vitro effects of mycophenolic acid on cell cycle and activation of human lymphocytes. Clin Chim Acta. 2000;300:23-28. (Pubitemid 30665771)
24. Yang L, Wieland E, Shipkova M. A simple and rapid high performance liquid chromatographic procedure for determination of inosine 5′-monophospahte dehydrogenase activity in isolated human mononuclear blood cells (MBC). Ther Drug Monit. 2005;27:253.
25. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843. (Pubitemid 13033817)
26. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation. 2009;88:514-520.
27. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231-236. (Pubitemid 38248526)
28. Legendre C, Cohen D, Zeier M, et al. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies. Transplant Proc. 2007;39:1386-1391. (Pubitemid 46907923)
29. Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888-898. (Pubitemid 46481185)
30. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16. (Pubitemid 36139819)
31. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant. 2007;7:1822-1831. (Pubitemid 46905448)
32. Shipkova M, Wieland E, Schütz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33:1080-1081. (Pubitemid 32237755)
33. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357-1359. (Pubitemid 26383778)
34. Minami Y, Kono T, Miyazaki T, et al. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol. 1993;11:245-268.
35. Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004;36: 2137-2143. (Pubitemid 39094437)
36. Chadburn A, Inghirami G, Knowles DM. The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells. Hematol Pathol. 1992;6:193-202.
37. Fox DA, Hussey RE, Fitzgerald KA, et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol. 1984;133:1250-1256. (Pubitemid 14060073)
38. Mattern T, Scholz W, Feller AC, et al. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol. 1991;33:737-748.
39. Ohnuma K, Uchiyama M, Hatano R, et al. Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells. Biochem Biophys Res Commun. 2009;386:327-332.
40. Annunziato F, Galli G, Cosmi L, et al. Molecules associated with human Th1 or Th2 cells. Eur Cytokine Netw. 1998;9(suppl):12-16. (Pubitemid 28508757)
41. D'Elios MM, Josien R, Manghetti M, et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int. 1997;51:1876-1884. (Pubitemid 27252758)
42. Maiguma T, Yosida T, Otsubo K, et al. Evaluation of inosin-5'- monophosphate dehydrogenase activity during maintenance therapy with tacrolimus. J Clin Pharm Ther. 2010;35:79-85.
43. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and II isoforms in human leukocytes. Biochem Pharmacol. 2004;67:767-776. (Pubitemid 38125261)
44. Bremer S, Mandla R, Vethe NT, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation. 2008;85:55-61.